Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM's platform take

Brian Goodman, Patrick Baeuerle and Todd Foley weren’t exactly looking to start a radiopharmaceuticals company.

Rather, the team at MPM Capital — which had been known for its willingness to seed and incubate new ideas for battling cancer — was searching for technologies that could confer “CAR-T like efficacy” in solid tumors. They went through antibody-drug conjugates, cell therapies and T cell engagers but very quickly got hooked on something else: alpha emitting particles.